刘菲
一、个人简介
刘菲，博士，博士后，副教授，毕业于清华大学医学部&北京协和医学院药物研究所，世界中医药学会联合会道地药材多维评价专业委员会会员、中华中医药协会会员。长期从事中药药效物质基础的相关研究，先后对藤石松、马尾杉、粗糙马尾杉、龙骨马尾杉、鹿角杜鹃以及姜黄与莪术中的活性成分进行了系统研究，分离获得单体成分400余个，其中新成分100余个，包含5个新颖骨架类结构。主持国家自然科学基金、四川省自然科学基金、博士后基金面上项目、校基金等各级课题5项。课题组探索发现姜黄和莪术活血功效差异与其所含的倍半萜有关，并发现姜黄没药烷型倍半萜类成分具有显著的舒张血管作用，其作用机制与调控pi3k/akt/enos通路有关，为心脑血管疾病新药开发提供了苗头化合物。目前，以第一作者或通讯作者发表sci论文19篇，包括1区top期刊organic letters和2区期刊biomedicine & pharmacotherapy、bioorganic chemistry、journal of natural products等，且在tetrahedron中发表论文被选为封面文章。此外，以通讯作者发表中文核心期刊论文10余篇，申请专利2项。
二、代表性成果（可含承担项目、发表论文、论著、获奖等）
主持科研项目情况：
（1）四川省自然科学基金青年科学基金项目，2023nsfsc1773，基于钾离子通道的莪术倍半萜舒张血管作用研究，2023/01-2024/12，10万元，在研，主持
（2）成都中医药大学“杏林学者”学科人才科研提升计划，qjrc2021008，蓬莪术倍半萜化学成分及其活血功效研究，2021/10-2024/10，18万元，在研，主持
（3）国家自然科学基金青年科学基金项目，81903777，基于倍半萜“异型异效”研究姜黄和莪术活血功效差异的物质基础，2020/01-2022/12，21万元，已结题，主持
（4）中国博士后科学基金面上项目，2019m653362，活血类药姜黄和破血类药莪术功效差异的物质基础研究，2020/01-2021/05，8万元，已结题，主持
（5）成都中医药大学“杏林学者”学科人才科研提升计划，bsh2018009，蓬莪术抗肿瘤活性成分研究，2018/07-2020/06，6万元，已结题，主持
代表性论文：
(1) jin-feng chen#, fei liu#, ming-ming qiao, hong-zhen shu, xiao-cui li, cheng peng*, liang xiong*, vasorelaxant effect of curcubisabolanin a isolated from curcuma longa through the pi3k/akt/enos signaling pathway, journal of ethnopharmacology, 2022, 294: 115332.
(2) juan liu, ming-ming qiao, cheng peng, hong-zhen shu, chun-wang meng, fei liu*, liang xiong*, curcumanes e and f, two rare sesquiterpenoids with a dicyclo[3.3.1]nonane moiety, from curcuma longa and their vasorelaxant activities, frontiers in chemistry, 2022, 10: 995950.
(3) hong-zhen shu, cheng peng, lan bu, li guo, fei liu*, liang xiong*, bisabolane-type sesquiterpenoids: structural diversity and biological activity, phytochemistry, 2021, 192: 112927.
(4) fei liu#, jin-feng chen#, ming-ming qiao, hao-yu zhao, qin-mei zhou, li guo, cheng peng*, liang xiong*, seven pairs of new enantiomeric sesquiterpenoids from curcuma phaeocaulis, bioorganic chemistry, 2020, 99: 103820.
(5) fei zhou#, fei liu#, juan liu, yu-lin he, qin-mei zhou, li guo, cheng peng*, liang xiong*, stachydrine promotes angiogenesis by regulating the vegfr2/mek/erk and mitochondrial-mediated apoptosis signaling pathways in human umbilical vein endothelial cells, biomedicine & pharmacotherapy, 2020, 131: 110724.
(6) ming-ming qiao#, fei liu#, yu liu, li guo, qin-mei zhou, cheng peng*, liang xiong*, curcumane c and (±)-curcumane d, an unusual seco-cadinane sesquiterpenoid and a pair of unusual nor-bisabolane enantiomers with significant vasorelaxant activity from curcuma longa, bioorganic chemistry, 2019, 92: 103275.
(7) fei liu#, jin-feng chen#, yue wang, li guo, qin-mei zhou, cheng peng*, liang xiong*, cytotoxicity of lanostane-type triterpenoids and ergosteroids isolated from omphalia lapidescens on mda-mb-231 and hgc-27 cells, biomedicine & pharmacotherapy, 2019, 118: 109273.
(8) yu liu#, fei liu#, ming-ming qiao, li guo, ming-hua chen, cheng peng*, liang xiong*, curcumanes a and b, two bicyclic sesquiterpenoids with significant vasorelaxant activity from curcuma longa, organic letters, 2019, 21(4): 1197-1201.
(9) fei liu#, ya-nan wang#, yong li, shuang-gang ma, jing qu, yun-bao liu, chang-shan niu, zhong-hai tang, yu-huan li, li li, shi-shan yu*, triterpenoids from the twigs and leaves of rhododendron latoucheae by hplc‒ms‒spe‒nmr, tetrahedron, 2019, 75(2): 296-307.
(10) fei liu#, ya-nan wang#, yong li, shuang-gang ma, jing qu, yun-bao liu, chang-shan niu, zhong-hai tang, yu-huan li, li li, shi-shan yu*, minor nortriterpenoids from the twigs and leaves of rhododendron latoucheae, journal of natural products, 2018, 81(8): 1721-1733.